Lyme borreliosis, anaplasmosis, babesiosis, Borrelia miyamotoi disease, neoehrlichiosis, rickettsiosis, tick-borne encephalitis virus
Conditions
Interventions
None listed
Sponsors
ZonMW
Eligibility
Inclusion criteria
Inclusion criteria: Cases (n=150) • Subjects are =16 years old; • Subjects report a tick-bite acquired within the last 2 months; • Subjects report an objectified (measured rectally, orally, axillary or tympanic) fever (defined as =38.0°C) within the last 4 weeks, developed in the course of 4 weeks after tick-bite; • Subjects live or stay in the Netherlands during the course of the study. Controls (n=200) • Subjects are =16 years old; • Subjects report a tick-bite acquired within the last 2 months; • Subjects frequency match to cases by gender, age, province of residence and month of tick-bite acquirement; • Subjects live or stay in the Netherlands during the course of the study.
Exclusion criteria
Exclusion criteria: Cases • Subjects with evident signs or symptoms of another cause of the fever besides a TBD; • Subjects unable to provide informed consent or do not have sufficient proficiency in the Dutch language. Controls • Subjects develop an objectified (measured rectally, orally, axillary or tympanic) temperature >37.3°C within 4 weeks after the tick-bite; • Subjects with evident signs or symptoms of a currant infectious disease; • Subjects unable to provide informed consent or do not have sufficient proficiency in the Dutch language.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures the prevalence of the different TBDs tested in blood, urine, skin biopsy in a group of participants who develop fever within 4 weeks after tick-bite in the Netherlands, of whom other causes of the fever are excluded. This measurement will be compared to the prevalence of infection with the same TBPs between the different control groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes measures the long term sequelae and the clinical manifestations of the different TBD’s. This will be obtained from the questionnaires and information from the treating physicians and measured by laboratory tests, culture, molecular and serological analyses in both cases and control groups. An additional aim is to obtain clinical isolates of the different TBPs, and other materials from patients with well-defined other TBDs, for further research and development, improvement or validation of diagnostic tests. | — |
Contacts
Public ContactDieuwertje Hoornstra
Amsterdam UMC
Outcome results
None listed